Brief: Akeso Says Ivonescimab Plus Chemo Meets Primary Endpoint
26/08/2026 02:29
BRIEF-Akeso Says Ivonescimab Plus Chemo Meets Primary Endpoint Aug 26 (Reuters) - Akeso Inc 9926.HK:
IVONESCIMAB PLUS CHEMO MEETS PRIMARY ENDPOINT WITH SIGNIFICANT OS BENEFIT IN 1L BTC
Further company coverage: 9926.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals